Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Benchmark Initiates Coverage On Belite Bio with Buy Rating, Announces Price Target of $57

Benchmark analyst Bruce Jackson initiates coverage on Belite Bio (NASDAQ:BLTE) with a Buy rating and announces Price Target of $57.
byBenzinga Newsdesk
July 1, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Benchmark analyst Bruce Jackson initiates coverage on Belite Bio (NASDAQ:BLTE) with a Buy rating and announces Price Target of $57.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts